A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson’s Disease

<div>Overview of the proposed mechanism of clearance of <i>α</i>-synuclein. Autophagy is compromised in the A53T tg mouse model. Activating the GLP-1 and GIP receptors increases autophagy in neurons via CREB signalling, thereby reducing the levels of <i>α</i>-synuclein in the substantia nigra and the striatum.</div>

Parkinson’s Disease

fig10

Figure 10

Figure 10: A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson’s Disease 